Advertisement

Cholinergic Dysfunction in Parkinson’s Disease

  • Martijn L. T. M. MüllerEmail author
  • Nicolaas I. Bohnen
Neuroimaging (DJ Brooks)
Part of the following topical collections:
  1. Topical Collection on Neuroimaging

Abstract

There is increasing interest in the clinical effects of cholinergic basal forebrain and tegmental pedunculopontine complex (PPN) projection degeneration in Parkinson’s disease (PD). Recent evidence supports an expanded role beyond cognitive impairment, including effects on olfaction, mood, REM sleep behavior disorder, and motor functions. Cholinergic denervation is variable in PD without dementia and may contribute to clinical symptom heterogeneity. Early in vivo imaging evidence that impaired cholinergic integrity of the PPN associates with frequent falling in PD is now confirmed by human post-mortem evidence. Brainstem cholinergic lesioning studies in primates confirm the role of the PPN in mobility impairment. Degeneration of basal forebrain cholinergic projections correlates with decreased walking speed. Cumulatively, these findings provide evidence for a new paradigm to explain dopamine-resistant features of mobility impairments in PD. Recognition of the increased clinical role of cholinergic system degeneration may motivate new research to expand indications for cholinergic therapy in PD.

Keywords

α-Synuclein Acetylcholine Acetylcholinesterase Basal forebrain Brainstem Cognition Dementia with Lewy bodies Dopamine Falls Gait Lewy bodies Mood Nucleus basalis of Meynert Olfaction Parkinson’s disease Pedunculopontine nucleus Pontine tegmentum Positron emission tomography (PET) Posture Progressive supranuclear palsy REM sleep behavior disorder Single photon emission computed tomography (SPECT) Striatum Thalamus Cholinergic dysfunction 

Notes

Acknowledgments

This work was supported by National of Institutes of Health grants P01 NS015655 & R01 NS070856, the Michael J. Fox Foundation, and the Department of Veterans Affairs. The authors have no potential conflict of interest relevant to this article to disclose.

Compliance with Ethics Guidelines

Conflict of Interest

Martijn L.T.M. Müller declares that he has no conflict of interest. Nicolaas I. Bohnen declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59:591–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.PubMedCrossRefGoogle Scholar
  3. 3.
    Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221:564–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol. 1988;275:216–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Heckers S, Geula C, Mesulam MM. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol. 1992;325:68–82.PubMedCrossRefGoogle Scholar
  7. 7.
    de Lacalle S, Hersh LB, Saper CB. Cholinergic innervation of the human cerebellum. J Comp Neurol. 1993;328:364–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Fibiger HC. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res. 1982;257:327–88.PubMedGoogle Scholar
  9. 9.
    Lecourtier L, Kelly PH. A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci Biobehav Rev. 2007;31:658–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Mesulam MM, Mash D, Hersh L, et al. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol. 1992;323:252–68.PubMedCrossRefGoogle Scholar
  11. 11.
    Flores CM, Rogers SW, Pabreza LA, et al. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41:31–7.PubMedGoogle Scholar
  12. 12.
    Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:6–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Cortes R, Palacios JM. Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies. Brain Res. 1986;362:227–38.PubMedCrossRefGoogle Scholar
  14. 14.
    Cortes R, Probst A, Tobler HJ, Palacios JM. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Brain Res. 1986;362:239–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815–28.PubMedCrossRefGoogle Scholar
  16. 16.
    Kotagal V, Muller ML, Kaufer DI, et al. Thalamic cholinergic innervation is spared in Alzheimer disease compared with parkinsonian disorders. Neurosci Lett. 2012;514:169–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401–6.PubMedCrossRefGoogle Scholar
  18. 18.
    DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Mufson EJ, Ma SY, Dills J, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol. 2002;443:136–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Tiraboschi P, Hansen LA, Alford M, et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease. Neurology. 2000;55:1278–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer’s disease. Cereb Cortex. 1996;6:165–77.PubMedCrossRefGoogle Scholar
  22. 22.
    Geula C, Mesulam MM. Cortical cholinergic fibers in aging and Alzheimer’s disease: a morphometric study. Neuroscience. 1989;33:469–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221:555–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Holdorff B. Fritz Heinrich Lewy (1885–1950). J Neurol. 2006;253:677–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci. 1983;59:277–89.PubMedCrossRefGoogle Scholar
  26. 26.
    Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol. 1984;15:415–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol. 1985;17:163–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Tagliavini F, Pilleri G, Bouras C, Constantinidis J. The basal nucleus of Meynert in idiopathic Parkinson’s disease. Acta Neurol Scand. 1984;70:20–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Whitehouse PJ, Hedreen JC, White III CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983;13:243–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s Disease. Acta Neuropathol. 1983;61:101–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Jellinger K. The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1988;51:540–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Gai WP, Halliday GM, Blumbergs PC, et al. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson’s disease. Brain. 1991;114:2253–67.PubMedCrossRefGoogle Scholar
  33. 33.
    Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A. 1987;84:5976–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Zweig RM, Jankel WR, Hedreen JC, et al. The pedunculopontine nucleus in Parkinson’s disease. Ann Neurol. 1989;26:41–6.PubMedCrossRefGoogle Scholar
  35. 35.
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMedCrossRefGoogle Scholar
  36. 36.
    Zaccai J, Brayne C, McKeith I, et al. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology. 2008;70:1042–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69–79.PubMedCrossRefGoogle Scholar
  38. 38.
    Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy bodies vs pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol. 1997;56:499–508.PubMedCrossRefGoogle Scholar
  39. 39.
    Tiraboschi P, Hansen LA, Alford M, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59:946–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord. 1999;14:947–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol. 1999;46:62–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology. 2010;74:1416–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Mesulam MM, Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res. 1992;577:112–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem. 1986;47:263–77.PubMedCrossRefGoogle Scholar
  46. 46.
    Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40:399–410.PubMedCrossRefGoogle Scholar
  48. 48.
    Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73:273–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Marcone A, Garibotto V, Moresco RM, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer’s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis. 2012;31:387–99.PubMedGoogle Scholar
  51. 51.
    Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacology. 2004;29:108–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Kas A, Bottlaender M, Gallezot JD, et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson’s disease. J Cereb Blood Flow Metab. 2009;29:1601–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Fujita M, Ichise M, Zoghbi SS, et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann Neurol. 2006;59:174–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Meyer PM, Strecker K, Kendziorra K, et al. Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66:866–77.PubMedCrossRefGoogle Scholar
  55. 55.
    Asahina M, Suhara T, Shinotoh H, et al. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry. 1998;65:155–63.PubMedCrossRefGoogle Scholar
  56. 56.
    • Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson’s disease without dementia. J Cereb Blood Flow Metab. 2012;32:1609–17. This study shows that cholinergic loss is variable in nondemented PD patients. The heterogeneity of cholinergic losses across nondemented patients suggests that cholinergic treatment in these patients should be targeted.PubMedCrossRefGoogle Scholar
  57. 57.
    Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289:18–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Koerts J, Leenders KL, Brouwer WH. Cognitive dysfunction in nondemented Parkinson’s disease patients: controlled and automatic behavior. Cortex. 2009;45:922–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Sawamoto N, Piccini P, Hotton G, et al. Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain. 2008;131:1294–302.PubMedCrossRefGoogle Scholar
  60. 60.
    Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30:1–23.PubMedCrossRefGoogle Scholar
  61. 61.
    Ruberg M, Rieger F, Villageois A, et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and nondemented patients with Parkinson’s disease. Brain Res. 1986;362:83–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Mattila PM, Roytta M, Lonnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol. 2001;102:160–6.PubMedGoogle Scholar
  63. 63.
    Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253:242–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5-year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–69.PubMedCrossRefGoogle Scholar
  66. 66.
    Aubert I, Araujo DM, Cecyre D, et al. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. J Neurochem. 1992;58:529–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Whitehouse PJ, Martino AM, Wagster MV, et al. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: an autoradiographic study. Neurology. 1988;38:720–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Petrou M, Kotagal V, Bohnen NI. An update on brain imaging in parkinsonian dementia. Imaging Med. 2012;4:201–13.PubMedCrossRefGoogle Scholar
  69. 69.
    Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord. 2008;23:1889–96.PubMedCrossRefGoogle Scholar
  70. 70.
    Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78:641–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Troster AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol. 1995;52:1164–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. 1981;31:645–50.PubMedCrossRefGoogle Scholar
  73. 73.
    Lieberman A. Are dementia and depression in Parkinson’s disease related? J Neurol Sci. 2006;248:138–42.PubMedCrossRefGoogle Scholar
  74. 74.
    Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord. 2005;20:1161–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord. 2009;15:490–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Doty R. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8:329–39.PubMedCrossRefGoogle Scholar
  77. 77.
    Bohnen NI, Muller ML. In vivo neurochemical imaging of olfactory dysfunction in Parkinson’s disease. J Neural Transm. 2013;120:571–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133:1747–54.PubMedCrossRefGoogle Scholar
  79. 79.
    Bohnen NI, Gedela S, Herath P, et al. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett. 2008;447:12–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Marion MH, Qurashi M, Marshall G, Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J Neurol. 2008;255:192–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Vendette M, Gagnon JF, Decary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology. 2007;69:1843–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Postuma RB, Gagnon JF, Montplaisir J. Cognition in REM sleep behavior disorder—a window into preclinical dementia? Sleep Med. 2008;9:341–2.PubMedCrossRefGoogle Scholar
  83. 83.
    • Kotagal V, Albin RL, Muller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol. 2012;71:560–8. To the best of our knowledge this is the first in vivo PET study to show that REM sleep behavior disorder (RBD) is associated with cholinergic denervation in PD. RBD is one of the first prodromal symptoms of Lewy body disorders. This result may indicate early cholinergic system degeneration in some patients.PubMedCrossRefGoogle Scholar
  84. 84.
    Postuma RB, Gagnon JF, Montplaisir JY. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis. 2012;46:553–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;70:2241–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord. 2008;23 Suppl 3:S521–33.PubMedCrossRefGoogle Scholar
  87. 87.
    •• Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest. 2010;120:2745–54. An elegant study that convincingly shows the role of the PPN in mobility impairment in parkinsonian monkeys and human patients with PD. Evidence for this is described in 3-fold in complementary human fMRI, human post-mortem, and primate lesioning studies. The finding that posture and gait deficits can occur with isolated PPN impairment in the absence of nigrostriatal dopaminergic lesions has major implications for current understanding of mobility impairments in PD.PubMedCrossRefGoogle Scholar
  88. 88.
    Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Bakker M, de Lange FP, Stevens JA, et al. Motor imagery of gait: a quantitative approach. Exp Brain Res. 2007;179:497–504.PubMedCrossRefGoogle Scholar
  90. 90.
    Cremers J, D’Ostilio K, Stamatakis J, et al. Brain activation pattern related to gait disturbances in Parkinson’s disease. Mov Disord. 2012;27:1498–505.PubMedCrossRefGoogle Scholar
  91. 91.
    Snijders AH, Leunissen I, Bakker M, et al. Gait-related cerebral alterations in patients with Parkinson’s disease with freezing of gait. Brain. 2011;134:59–72.PubMedCrossRefGoogle Scholar
  92. 92.
    Bohnen N, Kotagal V, Albin R, et al. Gait speed is preserved in oligosystem compared with multisystem neurodegeneration in Parkinson disease. Neurology. 2013;80, P04165.Google Scholar
  93. 93.
    Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture. 2002;16:1–14.PubMedCrossRefGoogle Scholar
  94. 94.
    Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson’s disease? Mov Disord. 2013. doi: 10.1002/mds.25360.
  95. 95.
    Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain. 2012;135:2779–88.PubMedCrossRefGoogle Scholar
  96. 96.
    Albin RL, Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson’s disease. J Cereb Blood Flow Metab. 2008;28:441–4.PubMedCrossRefGoogle Scholar
  97. 97.
    Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107–12.PubMedCrossRefGoogle Scholar
  98. 98.
    Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson’s disease dementia. NeuroImage. 2008;39:1027–33.PubMedCrossRefGoogle Scholar
  99. 99.
    Mann DM, Yates PO, Hawkes J. The pathology of the human locus ceruleus. Clin Neuropathol. 1983;2:1–7.PubMedGoogle Scholar
  100. 100.
    Muller ML, Frey KA, Petrou M, et al. β-amyloid and postural instability and gait difficulty in Parkinson’s disease at risk for dementia. Mov Disord. 2013;28:296–301.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Martijn L. T. M. Müller
    • 1
    Email author
  • Nicolaas I. Bohnen
    • 1
    • 2
    • 3
  1. 1.Functional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Division of Nuclear MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of NeurologyUniversity of MichiganAnn ArborUSA
  3. 3.Neurology Service and GRECCVAAAHSAnn ArborUSA

Personalised recommendations